Wahi a kahi hōʻike e ka Italian daily, Il Corriere della Sera, aia nā pūhui i loko o nā mea hoʻonaninani, nā lāʻau lapaʻau, a me nā meaʻai e hiki ai ke hoʻoulu i ka maʻi maʻi maʻi COVID i kekahi poʻe ma muli o ka ʻike mua. ʻO ka mea ma hope o nā hopena maʻi i hoʻomohala ʻia e kekahi poʻe ma hope o ka loaʻa ʻana o ka Pfizer Kano COVID ua ʻike ʻia paha. ʻO kēia ka pūhui "polyethylene glycol", i ʻike ʻia ʻo PEG.

ʻO ka hui maʻamau i nā mea hoʻonaninani

ʻOiai ke noiʻi mau nei nā luna olakino, e like me ka hana ʻana o ka hui lāʻau lapaʻau ponoʻī, ʻike mākou hiki ke hoʻopili ʻia ka PEG i kahi ala kakaʻikahi me nā hopena maʻi e like me ka mea i hōʻoia ʻia e Peter Marks, Luna Hoʻokele o ka Center for Product Evaluation and Research, US Food and Drug Administration. (FDA) huahana olaola.

He ʻoi aku ka maʻamau o kēlā mau maʻi maʻi ma mua o nā maʻi kakaʻikahi e kū mau. Loaʻa ka hui i nā shampoos, toothpastes, a me nā huahana ʻē aʻe he nui. ʻOi aku ka maʻalahi o kekahi poʻe no ka mea he kiʻekiʻe ko lākou kiʻekiʻe o nā antibodies i ka PEG. Ma nā lāʻau lapaʻau ʻelua, ʻo Pfizer-BioNTech a me Moderna, ʻo PEG kahi ʻāpana o ka envelop momona e hoʻopuni ana i ka ʻelele RNA, ka mea nui o ka maʻi.

Ke komo ka mRNA i loko o nā keena, aʻo ia iā lākou e hana i kahi protein e like me ka protein spike i loaʻa ma ka ʻili o ka coronavirus. Hoʻoulu kēia i kahi pane kūlohelohe kūikawā e hoʻoikaika ai i nā pale o ke kino ke ʻike ʻia i ka maʻi maʻi maoli. ʻO ka enveloppe momona i loaʻa ka PEG e kōkua i ka hōʻoia ʻana i ka hele ʻana o ka mRNA i ka membrane cell. ʻAʻole i hoʻohana ʻia ka PEG i kahi kano i ʻāpono ʻia ma mua, akā loaʻa ia i loko o nā lāʻau lapaʻau he nui. E hana ʻia nā haʻawina i nā pule e hiki mai ana i ka poʻe i loaʻa nā kiʻekiʻe kiʻekiʻe o ka anti-PEG antibodies a i ʻole i ʻike i nā pane maʻi maʻi koʻikoʻi i nā lāʻau lapaʻau a i ʻole nā lāʻau lapaʻau ma mua.

Nā hihia o ka maʻi maʻi

Hiki ke loaʻa nā hopena anaphylactic me nā kano āpau akā he mea kakaikahi loa - ma kahi o 1 i ka 1 miliona mau kau. Ma ka lā 19 o Dekemaba, 2020, ua ʻike ʻo ʻAmelika Hui Pū ʻIa i 6 mau maʻi anaphylaxis ma waena o 272,001 poʻe i loaʻa i ka lāʻau lapaʻau a ua loaʻa iā United Kingdom he 2 mau hihia ma nā haʻawina Phase 3 i alakaʻi ʻia i ka ʻae ʻia ʻana o nā kano i kāpae ʻia. Me ka mōʻaukala o nā allergies i nā ʻāpana lāʻau lapaʻau, no laila, ʻaʻole i hōʻike ʻia kahi pūʻulu o nā kānaka.

Ke hoʻonui nei ka nui o nā huahana biopharmaceutical me nā PEG. Wahi a kahi noiʻi 2016 i mālama ʻia ma ke Kulanui o North Carolina, Chapel Hill, 72% o nā kānaka i ka liʻiliʻi o kekahi mau antibodies i nā PEG, ma muli paha o ka ʻike ʻana i nā mea hoʻonaninani a me nā lāʻau lapaʻau. Ma kahi o 7% ka pae i hiki ke kiʻekiʻe e hiki ke hoʻomaka i ka hopena anaphylactic.

Nā ʻōlelo aʻoaʻo

ʻAʻohe mau mea paʻa akā he mau manaʻo wale nō: ʻike kekahi mau ʻepekema ʻo ka nui o ka PEG i loko o nā maʻi mRNA he haʻahaʻa ma mua o ka mea i loaʻa i ka hapa nui o nā lāʻau lapaʻau. I kēia manawa, ke aʻo ʻia nei nā mea ʻē aʻe i ka PEG, akā ʻaʻole i pau ka hoʻolaha ʻana i ka lāʻau lapaʻau, no ka mea, ʻoi aku ka nui o nā pōmaikaʻi ma mua o nā pilikia a ua hoʻōla ʻia nā mea a pau i loaʻa i kahi hopena maʻi.

Nā alakaʻi mai ka Nā Centers for Disease Control and Prevention (CDC) USA ʻaʻole e hāʻawi i nā lāʻau lapaʻau Pfizer a i ʻole Moderna i kekahi me ka moʻolelo o ka hopena maʻi koʻikoʻi i kekahi ʻāpana o ke kano. ʻAʻohe kumu e loaʻa ʻole ai i ka poʻe i loaʻa ka moʻolelo o ka maʻi maʻi maʻi a koʻikoʻi paha i ka meaʻai, nā holoholona, nā lāʻau lapaʻau waha, a i ʻole nā allergens kaiapuni e loaʻa ʻole i ka lāʻau lapaʻau i ʻōlelo ʻia e ka CDC. A ʻo ka poʻe i hiki ke loaʻa i ka hopena anaphylactic, pono lākou e noho ma ke kahua o ka lāʻau lapaʻau no 30 mau minuke ma hope o ka ʻinikua (a ʻaʻole ka "canonical" 15 wale nō).

ʻO COVID, ka "English variant," aia ma Lombardy: ʻelua mau hihia mua i ʻike ʻia

Ua ʻike ʻia ka ʻano coronavirus e San Matteo o Pavia. ʻO ka mea i kapa ʻia ʻo "English variant" o ka Sars-CoV-2 coronavirus, ka maʻi i kuleana no COVID, ua ʻike pū ʻia ma Lombardy. Hāʻawi ʻia ka nūhou e ka Policlinico San Matteo ma Pavia.

ʻO nā hihia mua ʻelua he 2 mau kamaʻāina Italia i pae i Malpensa i kēia mau lā - pololei ma Dekemaba 23 a me 24. ʻO nā hanana 2, wehewehe i ka haukapila, "kūʻokoʻa kekahi i kekahi a ʻaʻole pili i kahi maʻi maʻi."

Ua ho'āʻo maikaʻi ʻia nā laʻana no ka swab molecular i hoʻouna ʻia e ka ATS Insubria i ka IRCCS Policlinico San Matteo Foundation ma Pavia kahi i hana ai ka hui o Polofesa Fausto Baldanti i ke kaʻina.

ʻO ka mea i kapa ʻia ʻo "English variant" i ʻike ʻia i nā lā i hala aku nei ma nā ʻāpana Italia like ʻole (ma Lazio, Abruzzo, Campania, Veneto, Marche, a me Puglia), a ua pālahalaha ʻia ma nā wahi ʻē aʻe a me ka lāhui. ʻāina.

Wahi a nā haʻawina i loaʻa i kēia manawa a me ka poʻe loea i nīnauele ʻia e ka Corriere della Sera, he mana diffusion kēia ʻano i hiki ke kiʻekiʻe (a hiki i 70%). ʻAʻohe mea hōʻike e ʻoi aku ka pōʻino a i ʻole ka make, ʻaʻole hiki ke kūʻē i nā kano i ʻae ʻia a i ʻole ke ʻae ʻia e kūʻē iā COVID.

ʻAʻole maopopo inā i puka mai ka ʻano like ʻole ma Great Britain, akā naʻe, ua ʻike ʻia ma laila a lilo i mea nui ma ka ʻaoʻao hema o ka ʻāina. Ma waena o nā kuhiakau o kona kumu, ua haʻi ka European Center for the Surveillance of Infectious Diseases i ka hiki ke hoʻomohala ʻia i loko o kahi mea maʻi immunosuppressed ka mea i loaʻa i ka maʻi maʻi no ka manawa lōʻihi ma mua o ka hoʻihoʻi ʻana, makemake i ka hōʻiliʻili ʻana o nā mutations liʻiliʻi.

Ma muli o kona laha ʻana, ua hoʻokumu ke aupuni Pelekane i nā hana paʻa paʻa i ka hopena pule i hala. Ua hana ka European Union i nā hana e kaupalena i ka huakaʻi ma waena o Great Britain a me nā ʻāina EU i ka liʻiliʻi.

ʻO nā hihia 2 i hōʻike ʻia e Policlinico San Matteo i ʻike ʻia ma hope o ke komo ʻana i kēia mau lula.

Ma Dekemaba 26, 2020, ua hoʻoholo ʻo Iapana e pani i kona mau palena i nā haole a hiki i Ianuali 31, 2021, ma hope o ka ʻike ʻia ʻana o ka "ʻano Pelekane" hou i kekahi mau kaʻa e hōʻea mai ana mai Great Britain.

# pūnaehulehu